Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges
The DOI matches its Crossref record; 176 of the 177 references it cites were found in a registry or an index.
Abstract
In vivo gene replacement for the treatment of inherited disease is one of the most compelling concepts in modern medicine. Adeno-associated virus (AAV) vectors have been extensively used for this purpose and have shown therapeutic efficacy in a range of animal models. Successful translation to the clinic was initially slow, but long-term expression of donated genes at therapeutic levels has now been achieved in patients with inherited retinal disorders and haemophilia B. Recent exciting results have raised hopes for the treatment of many other diseases. As we discuss here, the prospects and challenges for AAV gene therapy are to a large extent dependent on the target tissue and the specific disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This immune cascade model might explain why re-administration in patients could become difficult, and why the administration of rAAVs in patients with high neutralizing antibodies (nAbs) are generally not included in clinical trials [327].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [327]
Citations
Cites
The Danger Model: A Renewed Sense of Self
Matzinger, P. (2002) · Science · doi:10.1126/science.1071059 · Cited by 4,205
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Genome editing with engineered zinc finger nucleases
Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S., & Gregory, P. D. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2842 · Cited by 2,285
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationSafety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Self-citationProphylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067659 · Cited by 1,950 · cited 1×
“The disease is currently treated by intravenous infusion of clotting factor concentrate”
BackgroundEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A. (2006) · Nature · doi:10.1038/nature04791 · Cited by 1,677
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Research works printed but not linked: 3
- Basner-Tschakarjan, E. et al. Dose-dependent activation of capsid-specific T cells after AAV serotype 8 vector administration in a clinical study for hemophilia. Mol. Ther. (in the press).
- Mingozzi, F. et al. Modulation of T cell response to the AAV capsid in subjects undergoing intramuscular gene transfer for lipoprotein lipase deficiency. Hum. Gene Ther. 19, 1090 (2008).
- Muzyczka, N. & Berns, K. I. in Parvoviridae: The Viruses and their Replication (eds Knipe, D. M. & Howley, P. M.) 2437–2477 (Lippincott, Williams and Wilkins, Philadelphia, 2001).
Cited by
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
“For this purpose, adeno-associated virus (AAV) vectors are attractive vehicles 10 because of their low immunogenic potential, reduced oncogenic risk from host-genome integration 11 , and broad-range of serotype specificity 12–15 .”
BackgroundAdeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362
“(SPK-9001, SPK-8011), Sangamo Therapeutics (SB-525), UniQure (AMT-060), Dimension Therapeutics (DTX101, DTX201), and Biomarin (BMN 270) (Table 3) [97].”
BackgroundMethodGene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184
In vivo gene editing in dystrophic mouse muscle and muscle stem cells
Tabebordbar, M., Zhu, K., Cheng, J. K. W., Chew, W. L., Widrick, J. J., Yan, W. X., Maesner, C., Wu, E. Y., Xiao, R., Ran, F. A., et al. (2016) · Science · doi:10.1126/science.aad5177 · Cited by 1,046
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
“10,11 As one would predict, the in vivo administration of a viral vector necessitates grappling at close quarters with the human immune response to foreign antigens.”
Self-citationNon Viral Vectors in Gene Therapy- An Overview
Ramamoorth, M. (2015) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2015/10443.5394 · Cited by 761
Current prospects for RNA interference-based therapies
Davidson, B. L., & McCray, P. B. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2968 · Cited by 761
Intracellular Delivery by Membrane Disruption: Mechanisms, Strategies, and Concepts
Stewart, M. P., Langer, R., & Jensen, K. F. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00678 · Cited by 747
Tham, Y. K., Bernardo, B. C., Ooi, J. Y. Y., Weeks, K. L., & McMullen, J. R. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1477-x · Cited by 708
Pope, H. G., Wood, R. I., Rogol, A., Nyberg, F., Bowers, L., & Bhasin, S. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1058 · Cited by 658
State-of-the-art gene-based therapies: the road ahead
Kay, M. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2971 · Cited by 666
Advances in the delivery of RNA therapeutics: from concept to clinical reality
Kaczmarek, J. C., Kowalski, P. S., & Anderson, D. G. (2017) · Genome Medicine · doi:10.1186/s13073-017-0450-0 · Cited by 656
“AAVs are most widely used for gene therapy clinical trials due to their ability to transduce different cell types and tissues and their low risk of genomic integration and low immunogenicity [153].”
BackgroundAAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
Self-citationTargeting long non-coding RNA to therapeutically upregulate gene expression
Wahlestedt, C. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4018 · Cited by 532
Entering the Modern Era of Gene Therapy
Anguela, X. M., & High, K. A. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-012017-043332 · Cited by 471
Self-citationThe AAV Vector Toolkit: Poised at the Clinical Crossroads
Asokan, A., Schaffer, D. V., & Jude Samulski, R. (2012) · Molecular Therapy · doi:10.1038/mt.2011.287 · Cited by 465
Chiappini, C., De Rosa, E., Martinez, J. O., Liu, X., Steele, J., Stevens, M. M., & Tasciotti, E. (2015) · Nature Materials · doi:10.1038/nmat4249 · Cited by 446
Treatment of a metabolic liver disease by in vivo genome base editing in adult mice
Villiger, L., Grisch-Chan, H. M., Lindsay, H., Ringnalda, F., Pogliano, C. B., Allegri, G., Fingerhut, R., Häberle, J., Matos, J., Robinson, M. D., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0209-1 · Cited by 429
Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy
Chandler, R. J., LaFave, M. C., Varshney, G. K., Trivedi, N. S., Carrillo-Carrasco, N., Senac, J. S., Wu, W., Hoffmann, V., Elkahloun, A. G., Burgess, S. M., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79213 · Cited by 403
“AAVs have therefore emerged as promising vectors for gene delivery (2) and have been extensively studied in small-and large-animal models for preclinical efficacy and safety (3).”
Extracellular Metabolic Energetics Can Promote Cancer Progression
Loo, J. M., Scherl, A., Nguyen, A., Man, F. Y., Weinberg, E., Zeng, Z., Saltz, L., Paty, P. B., & Tavazoie, S. F. (2015) · Cell · doi:10.1016/j.cell.2014.12.018 · Cited by 393
“Interestingly, the liver represents an exception to this rule, because miRNAs tend to accumulate in hepatic tissue and because vectors such as adeno-associated viruses and nanoparticles have shown promising efficacy in enhancing hepatic delivery in nonhuman primates and humans (Kota et al., 2009; Mingozzi and High, 20…”
Ex vivo gene transfer and correction for cell-based therapies
Naldini, L. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2985 · Cited by 358
Peptide-based nanomaterials: Self-assembly, properties and applications
Li, T., Lu, X.-M., Zhang, M.-R., Hu, K., & Li, Z. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.09.029 · Cited by 351
“However, RNA drugs are easily degraded and cannot penetrate cell membranes; there is an imperative need to develop efficient and biocompatible nucleic acid delivery systems [176].”
BackgroundNon-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets
Klingenberg, M., Matsuda, A., Diederichs, S., & Patel, T. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.04.009 · Cited by 354
“The adeno-associated virus (AAV) 8 serotype has a strong tropism for the liver, can be administered intravenously [199] and hence is appealing for targeting the liver.”
BackgroundFGF21 gene therapy as treatment for obesity and insulin resistance
Jimenez, V., Jambrina, C., Casana, E., Sacristan, V., Muñoz, S., Darriba, S., Rodó, J., Mallol, C., Garcia, M., León, X., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708791 · Cited by 324
“Here, we took advantage of adeno-associated viral (AAV) vectors and their ability to mediate multi-year production of therapeutic proteins (Mingozzi & High, 2011; Naldini, 2015) to develop a gene therapy strategy for obesity and T2D based on FGF21 gene transfer to the liver, adipose tissue, or…”
BackgroundDual AAV-mediated gene therapy restores hearing in a DFNB9 mouse model
Akil, O., Dyka, F., Calvet, C., Emptoz, A., Lahlou, G., Nouaille, S., Boutet de Monvel, J., Hardelin, J.-P., Hauswirth, W. W., Avan, P., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817537116 · Cited by 300
Adeno-Associated Virus-Based Gene Therapy for CNS Diseases
Hocquemiller, M., Giersch, L., Audrain, M., Parker, S., & Cartier, N. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.087 · Cited by 291
Hastie, E., & Samulski, R. J. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.025 · Cited by 280
Bioinspired exosome-like therapeutics and delivery nanoplatforms
Lu, M., & Huang, Y. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119925 · Cited by 282
CRISPR-Cas9 for cancer therapy: Opportunities and challenges
Chen, M., Mao, A., Xu, M., Weng, Q., Mao, J., & Ji, J. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.01.017 · Cited by 272
Senile Osteoporosis: The Involvement of Differentiation and Senescence of Bone Marrow Stromal Cells
Qadir, A., Liang, S., Wu, Z., Chen, Z., Hu, L., & Qian, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21010349 · Cited by 268
Viral vector‐based gene therapies in the clinic
Zhao, Z., Anselmo, A. C., & Mitragotri, S. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10258 · Cited by 269
Meliani, A., Boisgerault, F., Hardet, R., Marmier, S., Collaud, F., Ronzitti, G., Leborgne, C., Costa Verdera, H., Simon Sola, M., Charles, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06621-3 · Cited by 265
Self-citationAdvances in therapeutic CRISPR/Cas9 genome editing
Savić, N., & Schwank, G. (2016) · Translational Research · doi:10.1016/j.trsl.2015.09.008 · Cited by 257
Extracellular vesicles and intercellular communication within the nervous system
Zappulli, V., Friis, K. P., Fitzpatrick, Z., Maguire, C. A., & Breakefield, X. O. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81134 · Cited by 255
VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond
Giacca, M., & Zacchigna, S. (2012) · Gene Therapy · doi:10.1038/gt.2012.17 · Cited by 252
Mitochondrial diseases: from molecular mechanisms to therapeutic advances
Wen, H., Deng, H., Li, B., Chen, J., Zhu, J., Zhang, X., Yoshida, S., & Zhou, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02044-3 · Cited by 222
Clarifying lysosomal storage diseases
Schultz, M. L., Tecedor, L., Chang, M., & Davidson, B. L. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2011.05.006 · Cited by 245
Thakral, S., & Ghoshal, K. (2015) · Current Gene Therapy · doi:10.2174/1566523214666141224095610 · Cited by 235
“Among different viral vectors, the AAV8 serotype showed the most promising results for gene therapy in the liver as it has a strong tropism for liver and can be administered intravenously [52].”
BackgroundAllele-Specific Silencing of Mutant Myh6 Transcripts in Mice Suppresses Hypertrophic Cardiomyopathy
Jiang, J., Wakimoto, H., Seidman, J. G., & Seidman, C. E. (2013) · Science · doi:10.1126/science.1236921 · Cited by 232
Wright, J. (2014) · Biomedicines · doi:10.3390/biomedicines2010080 · Cited by 219
MultiBac: expanding the research toolbox for multiprotein complexes
Bieniossek, C., Imasaki, T., Takagi, Y., & Berger, I. (2012) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.10.005 · Cited by 216
“By contrast, recombinant adeno-associated virus (rAAV) does not have the drawbacks of baculovirus and is currently the best choice for efficient gene delivery for gene therapy [47] .”
BackgroundWhole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy
Haurigot, V., Marcó, S., Ribera, A., Garcia, M., Ruzo, A., Villacampa, P., Ayuso, E., Añor, S., Andaluz, A., Pineda, M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66778 · Cited by 215
“In vivo gene therapy offers the possibility of a one-time treat-ment for MPS IIIA and other inherited diseases, with the prospect of lifelong beneficial effects (14).”
Self-citationMelamed, J. R., Yerneni, S. S., Arral, M. L., LoPresti, S. T., Chaudhary, N., Sehrawat, A., Muramatsu, H., Alameh, M.-G., Pardi, N., Weissman, D., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade1444 · Cited by 210
“Moreover, while viruses are extremely efficient cellular transducers, they risk integration into the host genome and are limited by their immunogenicity (44, 80).”
BackgroundOvercoming innate immune barriers that impede AAV gene therapy vectors
Muhuri, M., Maeda, Y., Ma, H., Ram, S., Fitzgerald, K. A., Tai, P. W. L., & Gao, G. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143780 · Cited by 212
“Capsid peptides are loaded onto MHC class II and presented to CD4+ T cells (Figure 3B) (6, 135, 136).”
BackgroundMicroRNAs in glioblastoma multiforme pathogenesis and therapeutics
Shea, A., Harish, V., Afzal, Z., Chijioke, J., Kedir, H., Dusmatova, S., Roy, A., Ramalinga, M., Harris, B., Blancato, J., et al. (2016) · Cancer Medicine · doi:10.1002/cam4.775 · Cited by 209
“Currently, rAAVs are being used in clinical trials for various diseases including muscular dystrophy, Parkinson’s, cystic fibrosis, and hemophilia B [133].”
BackgroundMingozzi, F., & High, K. A. (2017) · Annual Review of Virology · doi:10.1146/annurev-virology-101416-041936 · Cited by 206
Self-citationRamanathan, A., Nelson, A. R., Sagare, A. P., & Zlokovic, B. V. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00136 · Cited by 205
“Viral-mediated gene transfer methods, especially adeno-associated viral (AAV) systems have proven to be effective both in different peripheral cell types as well as in the CNS (Davidson et al., 2000; Mingozzi and High, 2011), are safe and more commonly used for targeted gene therapy.”
BackgroundInfluentialRecombinant Adeno-Associated Viral Integration and Genotoxicity: Insights from Animal Models
Chandler, R. J., Sands, M. S., & Venditti, C. P. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.009 · Cited by 203
“11,12 The rAAVs used in gene delivery are physically different and exhibit different characteristics relative to the wild-type AAV precursor (reviewed by Daya and Berns 13 ).”
In vivo prime editing of a metabolic liver disease in mice
Böck, D., Rothgangl, T., Villiger, L., Schmidheini, L., Matsushita, M., Mathis, N., Ioannidi, E., Rimann, N., Grisch-Chan, H. M., Kreutzer, S., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl9238 · Cited by 198
Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction
Fitzpatrick, Z., Leborgne, C., Barbon, E., Masat, E., Ronzitti, G., van Wittenberghe, L., Vignaud, A., Collaud, F., Charles, S., Simon Sola, M., et al. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.02.003 · Cited by 192
Self-citationDelivery and Specificity of CRISPR/Cas9 Genome Editing Technologies for Human Gene Therapy
Gori, J. L., Hsu, P. D., Maeder, M. L., Shen, S., Welstead, G. G., & Bumcrot, D. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.074 · Cited by 189
“The past decade witnessed the advancement of recombinant AAV vectors into clinical trials for inherited and acquired genetic diseases, including Leber Congenital Amaurosis Type 2, Hemophilia B, and Canavan’s disease.(50) In 2012, the first AAVbased gene therapy product was approved by the European Medicines Agency to…”
A largely random AAV integration profile after LPLD gene therapy
Kaeppel, C., Beattie, S. G., Fronza, R., van Logtenstein, R., Salmon, F., Schmidt, S., Wolf, S., Nowrouzi, A., Glimm, H., von Kalle, C., et al. (2013) · Nature Medicine · doi:10.1038/nm.3230 · Cited by 176
Synthetic CRISPR RNA-Cas9–guided genome editing in human cells
Rahdar, M., McMahon, M. A., Prakash, T. P., Swayze, E. E., Bennett, C. F., & Cleveland, D. W. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520883112 · Cited by 186
“5) that is enabled by discovery of effective 29base scrRNAs would be to exploit a delivery vector (such as AAV) to drive expression of Cas9 and the tracrRNA in transduced cells in either peripheral tissues (17, 45, 46) or within the nervous system (47).”
BackgroundInnate Immune Responses to AAV Vectors
Rogers, G. L., Martino, A. T., Aslanidi, G. V., Jayandharan, G. R., Srivastava, A., & Herzog, R. W. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00194 · Cited by 178
“REVIEW ARTICLE published: 19 September 2011 doi: 10.3389/fmicb.2011.00194 Innate immune responses to AAV vectors”
BackgroundInfluentialMünch, R. C., Janicki, H., Völker, I., Rasbach, A., Hallek, M., Büning, H., & Buchholz, C. J. (2013) · Molecular Therapy · doi:10.1038/mt.2012.186 · Cited by 179
Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery
Nidetz, N. F., McGee, M. C., Tse, L. V., Li, C., Cong, L., Li, Y., & Huang, W. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107453 · Cited by 174
AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia
Nawaz, W., Huang, B., Xu, S., Li, Y., Zhu, L., Yiqiao, H., Wu, Z., & Wu, X. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00508-1 · Cited by 167
Snijder, J., van de Waterbeemd, M., Damoc, E., Denisov, E., Grinfeld, D., Bennett, A., Agbandje-McKenna, M., Makarov, A., & Heck, A. J. R. (2014) · Journal of the American Chemical Society · doi:10.1021/ja502616y · Cited by 168
Rincon, M. Y., VandenDriessche, T., & Chuah, M. K. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvv205 · Cited by 167
“persistent transgene expression in a wide range of target tissues, including the heart.(39) Since they provoke much less inflammation compared”
BackgroundChicoine, L., Montgomery, C., Bremer, W., Shontz, K., Griffin, D., Heller, K., Lewis, S., Malik, V, Grose, W., Shilling, C., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2013.244 · Cited by 167
Martino, A. T., Basner-Tschakarjan, E., Markusic, D. M., Finn, J. D., Hinderer, C., Zhou, S., Ostrov, D. A., Srivastava, A., Ertl, H. C. J., Terhorst, C., et al. (2013) · Blood · doi:10.1182/blood-2012-10-460733 · Cited by 162
“AAV8 has strong tropism for the liver and is therefore widely considered for clinical applications, including current and future trials in hemophilia.(18,43,44) Poor in vitro transduction with AAV8 kept us from performing assays in hepatocyte cultures.”
BackgroundSelf-citationStanek, L. M., Sardi, S. P., Mastis, B., Richards, A. R., Treleaven, C. M., Taksir, T., Misra, K., Cheng, S. H., & Shihabuddin, L. S. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.200 · Cited by 162
“delivery portend the therapeutic potential of this strategy for neurodegenerative diseases (LeWitt et al., 2011; Mingozzi and High, 2011; Mittermeyer et al., 2012).”
BackgroundLau, C.-H., & Suh, Y. (2017) · F1000Research · doi:10.12688/f1000research.11243.1 · Cited by 161
Comparative Analysis of Adeno-Associated Virus Capsid Stability and Dynamics
Rayaprolu, V., Kruse, S., Kant, R., Venkatakrishnan, B., Movahed, N., Brooke, D., Lins, B., Bennett, A., Potter, T., McKenna, R., et al. (2013) · Journal of Virology · doi:10.1128/jvi.01415-13 · Cited by 160
“Interest in the use of other serotypes (AAV1, AAV5, AAV6, and AAV8, for example) is growing because of their different tissue specificities, cell transduction efficiencies, and antigenicities (5, 6, 11, 13, 14, 101).”
BackgroundImmunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
Osteoblast-Targeting-Peptide Modified Nanoparticle for siRNA/microRNA Delivery
Sun, Y., Ye, X., Cai, M., Liu, X., Xiao, J., Zhang, C., Wang, Y., Yang, L., Liu, J., Li, S., et al. (2016) · ACS Nano · doi:10.1021/acsnano.5b07828 · Cited by 157
Challenges in carrier‐mediated intracellular delivery: moving beyond endosomal barriers
Stewart, M. P., Lorenz, A. S., Dahlman, J. E., & Sahay, G. (2015) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1377 · Cited by 172
A Comprehensive Review on Intracellular Delivery
Rad, D. M., Rad, M. A., Bazaz, S. R., Kashaninejad, N., Jin, D., & Warkiani, M. E. (2021) · Advanced Materials · doi:10.1002/adma.202005363 · Cited by 171
Delivery is key: lessons learnt from developing splice‐switching antisense therapies
Godfrey, C., Desviat, L. R., Smedsrød, B. H., Piétri‐Rouxel, F., Denti, M. A., Disterer, P., Lorain, S., Nogales‐Gadea, G., Sardone, V., Anwar, R., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607199 · Cited by 166
“AAVs are promising vectors for in vivo therapeutic gene delivery and have been shown in a number of human clinical trials to deliver therapeutic genes to a variety of organs and tissues including the CNS, liver and muscle (Mingozzi & High, 2011).”
Liguore, W. A., Domire, J. S., Button, D. A., Wang, Y., Dufour, B. D., Srinivasan, S., & McBride, J. L. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.07.017 · Cited by 163
Beyond the brain: Optogenetic control in the spinal cord and peripheral nervous system
Montgomery, K. L., Iyer, S. M., Christensen, A. J., Deisseroth, K., & Delp, S. L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7577 · Cited by 147
“However, with the increasing availability of transgenic marmoset models (153, 154), and research efforts toward modifying AAVs for human use (155), it is likely that these difficulties will be overcome.”
BackgroundImmunity to CRISPR Cas9 and Cas12a therapeutics
Chew, W. L. (2017) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1408 · Cited by 163
The advent of AAV9 expands applications for brain and spinal cord gene delivery
Dayton, R. D., Wang, D. B., & Klein, R. L. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.681463 · Cited by 144
Mietzsch, M., Grasse, S., Zurawski, C., Weger, S., Bennett, A. D., Agbandje‐McKenna, M., Muzyczka, N., Zolotukhin, S., & Heilbronn, R. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.184 · Cited by 150
“…extended cell- and tissue-specific transduction patterns of alternative AAV serotypes are being increasingly translated into clinical gene therapy (Mingozzi and High, 2011; Nathwani et al., 2011). rAAV vectors are constructed as gene-deleted AAVs comprising the gene of interest flanked the…”
BackgroundHorowitz, E. D., Rahman, K. S., Bower, B. D., Dismuke, D. J., Falvo, M. R., Griffith, J. D., Harvey, S. C., & Asokan, A. (2013) · Journal of Virology · doi:10.1128/jvi.03017-12 · Cited by 139
“In the past 2 decades, AAV has been utilized as a gene transfer vector in a number of phase I and phase II clinical trials treating various genetic diseases (5).”
BackgroundMingozzi, F., Chen, Y., Edmonson, S. C., Zhou, S., Thurlings, R. M., Tak, P. P., High, K. A., & Vervoordeldonk, M. J. (2013) · Gene Therapy · doi:10.1038/gt.2012.55 · Cited by 138
“…years, remarkable progress has been made in the development of effective gene transfer strategies for the treatment of inherited and metabolic diseases, with some of the most exciting results of in vivo gene transfer in humans obtained using recombinant adeno-associated virus (AAV) vectors 3 .”
Self-citationHsu, P.-H., Wei, K.-C., Huang, C.-Y., Wen, C.-J., Yen, T.-C., Liu, C.-L., Lin, Y.-T., Chen, J.-C., Shen, C.-R., & Liu, H.-L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057682 · Cited by 136
“Recent human trials using rAAV-2 vectors all involved treatment of neurological disorders within large brain regions such as cortex, and found limited distribution of rAAV-2 after intracranial injection [1,4,7].”
BackgroundLocal gene therapy durably restores vestibular function in a mouse model of Usher syndrome type 1G
Emptoz, A., Michel, V., Lelli, A., Akil, O., de Monvel, J. B., Lahlou, G., Meyer, A., Dupont, T., Nouaille, S., Ey, E., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1708894114 · Cited by 141
Zhao, X., Liu, L., Lang, J., Cheng, K., Wang, Y., Li, X., Shi, J. Y., Wang, Y., & Nie, G. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.05.042 · Cited by 143
Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase
Puzzo, F., Colella, P., Biferi, M. G., Bali, D. S., Paulk, N. K., Vidal, P., Collaud, F., Sola, M. S., Charles, S., Hardet, R., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aam6375 · Cited by 149
“Liver has been successfully targeted using AAV vectors in a variety of preclinical and clinical studies such as those aimed at treating hemophilia B (13).”
BackgroundSelf-citationTseng, Y.-S., & Agbandje‐McKenna, M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00009 · Cited by 153
Gammage, P. A., Gaude, E., Haute, L. V., Rebelo‐Guiomar, P., Jackson, C. B., Rorbach, J., Pękalski, M. Ł., Robinson, A. J., Charpentier, M., Concordet, J., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw676 · Cited by 148
“Although the AAV is generally considered to be a transient, non-integrating genetic medium, it has been shown in animal models that viral genomes persist, in an episomal state, for essentially the entire life-span of the lab animal, most reliably in post-mitotic or slowly-dividing tissues (60).”
Millan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., & Ove Ögren, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.016 · Cited by 132
“Adenovirus-driven gene transfer and cell transplants, including genome-edited iPSCs, should also be mentioned (Maeder and Bumcrot, 2014; Mingozzi and High, 2011).”
BackgroundRogers, G. L., Shirley, J. L., Zolotukhin, I., Kumar, S. R. P., Sherman, A., Perrin, G. Q., Hoffman, B. E., Srivastava, A., Basner-Tschakarjan, E., Wallet, M. A., et al. (2017) · Blood · doi:10.1182/blood-2016-11-751040 · Cited by 131
Off-target-free gene delivery by affinity-purified receptor-targeted viral vectors
Münch, R. C., Muth, A., Muik, A., Friedel, T., Schmatz, J., Dreier, B., Trkola, A., Plückthun, A., Büning, H., & Buchholz, C. J. (2015) · Nature Communications · doi:10.1038/ncomms7246 · Cited by 140
Moreno, A. M., Palmer, N. D., Alemán, F., Chen, G., Pla, A., Jiang, N. J., Chew, W. L., Law, M., & Mali, P. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0431-2 · Cited by 134
Meliani, A., Boisgerault, F., Fitzpatrick, Z., Marmier, S., Leborgne, C., Collaud, F., Simon Sola, M., Charles, S., Ronzitti, G., Vignaud, A., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017010181 · Cited by 127
“Discussion Recombinant AAV are the most clinically relevant vectors for in vivo gene transfer, as demonstrated in several trials and in particular in the context of bleeding disorders.(1,2,10,12) Despite the excellent safety and efficacy profile, however, some important limitations of the technology remain, mainly ass…”
BackgroundSelf-citationTransformation-associated recombination (TAR) cloning for genomics studies and synthetic biology
Kouprina, N., & Larionov, V. (2016) · Chromosoma · doi:10.1007/s00412-016-0588-3 · Cited by 127
“They do not cause severe immunogenic responses, which have been a serious problem with viral-based vectors (Lufino et al. 2008; Buchholz et al. 2009; Wanisch and Yáñez-Muñoz 2009; Epstein 2009; Maier et al. 2010; Mingozzi et al. 2011; Zhang et al. 2014).”
BackgroundMorabito, G., Giannelli, S. G., Ordazzo, G., Bido, S., Castoldi, V., Indrigo, M. T., Cabassi, T., Cattaneo, S., Luoni, M., Cancellieri, C., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.08.004 · Cited by 140
Adeno-associated Virus Vectors in Gene Therapy
Mary, B., Khan, N., Arumugam, S., Saxena, H., Kumar, M., Manimaran, P., Chattopadhyay, S., & Jayandharan, G. R. (2018) · Springer eBooks · doi:10.1007/978-981-13-0481-1_2 · Cited by 127
Massively parallel cis-regulatory analysis in the mammalian central nervous system
Shen, S. Q., Myers, C. A., Hughes, A. E. O., Byrne, L. C., Flannery, J. G., & Corbo, J. C. (2015) · Genome Research · doi:10.1101/gr.193789.115 · Cited by 138
“AAV causes long-lasting infection in rodents and primates, and its tissue tropism ranges by serotype from promiscuous to cell-type selective (Mingozzi and High 2011).”
Yue, Y., Pan, X., Hakim, C. H., Kodippili, K., Zhang, K., Shin, J., Yang, H. T., McDonald, T., & Duan, D. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv310 · Cited by 131
“Localized gene transfer has resulted in miraculous improvements for diseases that affect a single organ (1,2).”
BackgroundMicrofluidic and Nanofluidic Intracellular Delivery
Hur, J., & Chung, A. J. (2021) · Advanced Science · doi:10.1002/advs.202004595 · Cited by 135
Applications of CRISPR-Cas Enzymes in Cancer Therapeutics and Detection
Huang, C., Lee, K.-C., & Doudna, J. A. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.05.006 · Cited by 127
“Although AAVs’ single-stranded DNA genome can serve as a donor for homology directed repair (HDR) and it can transduce different cell types in vivo such as eye, skeletal, liver, neuron, and cardiac muscle [69] with low risk of genomic integration [77], their small packaging size requires multiple viruses to deliver al…”
BackgroundMultiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity
Wang, G., Chow, R. D.-W., Bai, Z., Zhu, L., Errami, Y., Dai, X., Dong, M. B., Ye, L., Zhang, X., Renauer, P. A., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0500-4 · Cited by 124
Genome editing by natural and engineered CRISPR-associated nucleases
Wu, W. Y., Lebbink, J. H. G., Kanaar, R., Geijsen, N., & John van der, O. O. S. T. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0080-x · Cited by 124
Synthetic Aptamer-Polymer Hybrid Constructs for Programmed Drug Delivery into Specific Target Cells
Oh, S. S., Lee, B. F., Leibfarth, F. A., Eisenstein, M. S., Robb, M. J., Lynd, N. A., Hawker, C. J., & Soh, H. T. (2014) · Journal of the American Chemical Society · doi:10.1021/ja5079464 · Cited by 128
Meliani, A., Leborgne, C., Donnou, S., Jeanson, L., Veron, P., & Mingozzi, F. (2015) · Human Gene Therapy Methods · doi:10.1089/hgtb.2015.037 · Cited by 122
Self-citationAdeno-Associated Virus Structural Biology as a Tool in Vector Development
Drouin, L. M., & Agbandje-McKenna, M. (2013) · Future Virology · doi:10.2217/fvl.13.112 · Cited by 114
Metadata
- Authors
- Mingozzi, F., & High, K. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Corresponding author
- High, Katherine A.
- Venue
- Nature Reviews Genetics
- Published
- 2011-04-18
- Volume
- 12
- Issue
- 5
- Pages
- 341-355
- ISSN
- 1471-0056 (ISSN-L)
- 1471-0064
- OpenAlex
- W2012894204
- Cited by
- 893
- References
- 177
- Citations by year
- 2026: 13 · 2025: 30 · 2024: 51 · 2023: 39 · 2022: 43 · 2021: 53 · 2020: 66 · 2019: 62 · 2018: 66 · 2017: 80 · 2016: 70 · 2015: 82 · 2014: 74 · 2013: 73 · 2012: 65
- FWCI
- 7.96
- Type
- journal article
- Language
- en
- Update notices
- erratum (2011-05-24)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- National Heart, Lung, and Blood Institute (P01HL064190, HL64190, HL078810, P01HL078810)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Keywords
- adeno-associated virus vectors, gene therapy, in vivo gene delivery, genetic disorders, gene replacement, inherited retinal disease, hemophilia B
- MeSH terms
- Dependovirus, Animals, Hemophilia B, Clinical Trials as Topic, Dogs, Genetic Vectors, Humans, Male, Retinal Diseases, Genetic Therapy, Gene Transfer Techniques, Genetic Diseases, Inborn, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.